Table 1.
Baseline characteristics of HIV-infected Kenyan patients on Long-Term ART
| Baseline characteristics [Mean (SD)] | No PN (n=212) | PN-before ART (n=14) | PN-After ART (n=94) | Total N=320 | Differences No PN vs. PN after ART |
|---|---|---|---|---|---|
| Age (years) | 36.8±7.9 | 40.0±10.2 | 39.2±8.0 | 37.6±8.2 | t=-2.40 p=.017 |
| Gender (Female) [n(%)] | 148 (69.8%) | 14(100%) | 68(72.3%) | 230(71.9%) | χ=0.2 p=0.685 |
| Height (cm) | 163.0±8.8 | 159.6±11.8 | 162.1±8.1 | 162.6±8.7 | T=.83 p=.405 |
| BMI (kg/m2) | 24.1±4.3 | 24.8±3.5 | 24.4±4.4 | 24.3±4.3 | T=-.51, p=.608 |
| CD4 count (cells/mm3) | 240.0±102.4 (n=125) | 279.3±123.5 (n=7) | 235.4±103.4 (n=64) | 239.9±103.2 (n=196) | T=.30 p=.766 |
| Hemoglobin (g/dL) | 12.7±2.7 (n=125) | 13.3±3.2 (n=7) | 12.4±2.4 (n=64) | 12.6±2.6 (n=196) | T=.61 p=.583 |
| White blood cell count (tsd. cells/µl) | 5.4±2.5 (n=125) | 5.5±1.7 (n=7) | 5.6±2.6 (n=64) | 5.5±2.5 (n=196) | T=-.55 p=.583 |
| Platelet count (tsd. cells/µl) | 294.4±100.2 (n=118) | 339.6±87.2 (n=7) | 280.9±101.4 (n=57) | 291.9±100.2 (n=182) | T=.83 p=.407 |
| CD4/CD8 ratio | 0.28±0.17 (n=97) | 0.26±0.13 (n=7) | 0.29±0.18 (n=53) | 0.3±0.2 (n=157) | T=-.28 p=.778 |
| ART-initiated | |||||
| AZT-Based | 91(42.9%) | 4(28.6%) | 34(36.2%) | 129(40.3%) | χ=1.23 p=0.314 |
| d4T-Based | 104(49.1%) | 8(57.1%) | 43(45.7%) | 155(48.4%) | χ=0.29 p=0.593 |
| TDF-Based | 17(8%) | 2(14.3%) | 17(18.1%) | 36(11.3%) | χ=6.68 p=0.017 |
| 3TC-Based | 212(100%) | 14(100%) | 94(100%) | 320(100%) | |
| NVP-Based | 182(85.8%) | 12(85.7%) | 76(80.9%) | 270(84.4%) | χ=1.23 p=0.307 |
| EFV-Based | 30(14.2%) | 2(14.3%) | 18(19.1%) | 50(15.6%) | χ=1.23 p=0.307 |
| Time to first change of ART regime (months) | 37.7±13.8 | 32.4±18.5 | 34.7±17.0 | 36.8±14.9 | T=1.67 p=.097 |
| ART-duration (months) | 47.6±10.4 | 48.2±6.9 | 48.4±10.0 | 47.9±10.2 | T=-.64 p=.525 |
SD-standard deviation; n-number; BMI-body mass index; cm-centimeter; kg/m2-kilogram per square meter; bpm-beats per minute; mmHg-millimeters of mercury; CD4-cluster of differentiation-4; CD8-cluster of differentiation-8; g/dL-grams per deciliter; tsd cells/µl-thousand cells per microliter; AZT-zidovudine; d4T- stavudine; 3TC-lamivudine; TDF-tenoforvir disoproxil fumerate; NVP-nevirapine; EFV-efavirenz; ART-antiretroviral therapy; PN-polyneuropathy